65 completed, 43 recruiting, 26 active not recruiting, 26 terminated. 81 Phase 1, 78 Phase 2, 21 Phase 3, 16 Not applicable, 5 Phase 4.
Follow Non-small Cell Lung Cancer (NSCLC): new trials by email Literature Review of Non-small Cell Lung Cancer (NSCLC) trials Research Report on Non-small Cell Lung Cancer (NSCLC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation. GFH276, with or without Tislelizumab, Pemetrexed - RAS Mutation, Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 84 | 2026-11-01 | 2026-09-29 |
| MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC PD-1 inhibitor, Carboplatin, Nab-paclitaxel - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 100 | 2026-11-01 | 2026-10-21 |
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-10-28 | 2026-10-23 |
| A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss ponsegromab, placebo - Non-small Cell Lung Cancer (NSCLC), Cachexia | Phase 1 | Not yet recruiting | Pfizer | 80 | 2026-10-23 | 2026-09-25 |
| Wireless Wearable Home Prehabilitation for Older Adults With NSCLC Digital Home-Based Prehabilitation, Standard Perioperative Care - Non-Small Cell Lung Cancer (NSCLC), Rehabilitation | Not applicable | Recruiting | West China Hospital | 196 | 2026-09-10 | 2026-09-09 |
| Digital Rehabilitation With Wearable Monitors for Sequential Lung Cancer Resection Wireless Wearable Vital Sign and Activity Monitor, Digital Pulmonary Rehabilitation Program, Standard ERAS Perioperative and Rehabilitation Care - Non-Small Cell Lung Cancer (NSCLC), Rehabilitation | Not applicable | Not yet recruiting | West China Hospital | 222 | 2026-08-31 | 2026-09-01 |
| Rehabilitation With Wearable Monitors for Post-Lung Cancer Surgery Wireless Wearable Vital Sign and Activity Monitor, Digital Postoperative Rehabilitation Program, Standard Postoperative Rehabilitation Education - Non-Small Cell Lung Cancer (NSCLC), Rehabilitation | Not applicable | Not yet recruiting | West China Hospital | 126 | 2026-08-31 | 2026-09-02 |
| Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC For Part A - Observational Cohort:, Part B: Intensive Lipid-Lowering Group, For Part B - Intensive Group - Non-Small Cell Lung Cancer (NSCLC), Hyperlipidemia | Not yet recruiting | Sun Yat-sen University | 160 | 2026-08-01 | 2026-06-29 | |
| Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors LT-010391 - Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1 | Not yet recruiting | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | 198 | 2026-07-01 | 2026-06-03 |
| Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors 68Ga-DFC413, 68Ga-NNS309 - Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC) | Phase 1 | Recruiting | Novartis Pharmaceuticals | 66 | 2026-06-23 | 2026-08-27 |
| Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors [68Ga]Ga-DWJ155, [177Lu]Lu-DWJ155 - Breast Cancer, Non-small Cell Lung Cancer (NSCLC) | Phase 1 | Recruiting | Novartis Pharmaceuticals | 156 | 2026-06-16 | 2026-08-27 |
| A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation Setidegrasib, Docetaxel - Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 356 | 2026-04-28 | 2026-10-20 |
| Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors EXS74539 - Solid Tumor, Small Cell Lung Cancer (SCLC) | Phase 1 | Recruiting | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 40 | 2026-04-13 | 2026-06-10 |
| QLS5132 Combination Therapy in Advanced Solid Tumors QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab - Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 626 | 2026-04-01 | 2026-03-06 |
| A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors IDE574, Fulvestrant injection - ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC) | Phase 1 | Recruiting | IDEAYA Biosciences | 160 | 2026-03-17 | 2026-06-16 |
| A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) Pumitamig, Durvalumab - Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Recruiting | Bristol-Myers Squibb | 850 | 2026-03-16 | 2026-09-30 |
| A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) Pumitamig, Pembrolizumab - Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Recruiting | Bristol-Myers Squibb | 750 | 2026-03-12 | 2026-10-23 |
| Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK - Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 85 | 2026-02-01 | 2026-02-18 |
| Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors Daraxonrasib, Elironrasib, Zoldonrasib - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 370 | 2026-01-30 | 2026-08-03 |
| Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer Rina-S - Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Recruiting | Genmab | 240 | 2026-01-30 | 2026-10-06 |
Showing 20 of 208. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (208) · Colorectal Neoplasms (23) · Lung Neoplasms (23) · Neoplasm Metastasis (19) · Melanoma (16) · Squamous Cell Carcinoma of Head and Neck (15) · Neoplasms (14) · Ovarian Neoplasms (14) · Stomach Neoplasms (12) · Pancreatic Neoplasms (11) · Triple Negative Breast Neoplasms (10) · Esophageal Neoplasms (9) · Carcinoma, Renal Cell (8) · Breast Neoplasms (7) · Endometrial Neoplasms (7)
Bronchial Neoplasms (206) · Carcinoma, Bronchogenic (206) · Respiratory Tract Diseases (205) · Respiratory Tract Neoplasms (205) · Lung Diseases (204) · Neoplasms by Site (204) · Thoracic Neoplasms (203) · Neoplasms (194) · Lung Neoplasms (185) · Digestive System Diseases (38) · Digestive System Neoplasms (38) · Neoplasms by Histologic Type (38) · Gastrointestinal Diseases (36) · Gastrointestinal Neoplasms (32) · Pathological Conditions, Signs and Symptoms (31)
Carboplatin (19) · Pemetrexed (17) · pembrolizumab (14) · Nivolumab (13) · Cisplatin (12) · Docetaxel (10) · Paclitaxel (10) · Bevacizumab (8) · Gemcitabine (8) · durvalumab (8) · Cetuximab (6) · atezolizumab (6) · Ipilimumab (5) · osimertinib (5) · 130-nm albumin-bound paclitaxel (4)
Bristol-Myers Squibb (12) · Takeda (9) · Hoffmann-La Roche (8) · Novartis Pharmaceuticals (8) · AstraZeneca (6) · Revolution Medicines, Inc. (6) · Daiichi Sankyo (5) · Astellas Pharma Global Development, Inc. (4) · Merck Sharp & Dohme LLC (4) · West China Hospital (4) · Abramson Cancer Center at Penn Medicine (3) · Genmab (3) · National Taiwan University Hospital (3) · Pfizer (3) · Sun Yat-sen University (3)
United States (103) · China (57) · Spain (41) · France (36) · Italy (32) · South Korea (32) · Japan (30) · Taiwan (30) · United Kingdom (28) · Australia (27) · Canada (27) · Germany (26) · Poland (19) · Netherlands (18) · Thailand (15)
Revolution Medicines, Inc. (4) · Chih-Hsin Yang, MD, PhD (2) · Marc de Perrot, MD, FRCSC (2) · Abraham Chachoua, MD (1)
PMID 37590355, PMID 40056080, PMID 11110430, PMID 14688713, PMID 17306905, PMID 17704125, PMID 20881641, PMID 21597387, PMID 22512843, PMID 25195590, PMID 25546556, PMID 27543256, PMID 28360208, PMID 28468947, PMID 28696575, PMID 28911085, PMID 29700655, PMID 29732193, PMID 31046714, PMID 31070709, PMID 31399043, PMID 31618297, PMID 32802427, PMID 32802440, PMID 32916310, PMID 33529989, PMID 34489161, PMID 34677350, PMID 34761878, PMID 35254415, PMID 35362047, PMID 35584349, PMID 35688554, PMID 35961520, PMID 36054490, PMID 36892745, PMID 37301638, PMID 37707820, PMID 38261467, PMID 38360680, PMID 38589574, PMID 38593348, PMID 38615547, PMID 38764164, PMID 38828959, PMID 38883662, PMID 38927985, PMID 39462179, PMID 40023002, PMID 40347227
2023 (8), 2019 (7), 2025 (6), 2018 (4), 2015 (2), 2016 (2)